Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)

Market Cap	44.78B
Revenue (ttm)	8.13B
Net Income (ttm)	2.00B
Shares Out	6.60B
EPS (ttm)	0.30
PE Ratio	22.52
Forward PE	18.04
Dividend	0.07 (0.98%)
Ex-Dividend Date	Sep 30, 2024

Volume	25,201,600
Average Volume	40,416,931
Open	6.82
Previous Close	6.78
Day's Range	6.79 - 6.83
52-Week Range	6.42 - 8.68
Beta	0.51
RSI	45.59
Earnings Date	Apr 18, 2025

About SHE:002252

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 3,350
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002252

Financial Performance

In 2024, SHE:002252's revenue was 8.18 billion, an increase of 2.67% compared to the previous year's 7.96 billion. Earnings were 2.19 billion, an increase of 23.25%.